Use of betablockers in elderly patients with congestive heart failure;Uso de bloqueadores beta en pacientes ancianos con insuficiencia cardíaca

Medicina Clinica

Volumn 126, Issue 6, 2006, Pages 206-210

  Urrutia, Agustín ^a   Lupón, Josep ^a   Altimir, Salvador ^a   González, Beatriz ^a   Herreros, Joan ^a   Díez, Crisanto ^a   Coll, Ramón ^a   Valle, Vicente ^a   Rey Joly, Celestino ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Betablockers; Congestive heart failure; Elderly patients

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; METOPROLOL;

AGED; AORTA STENOSIS; ARTERY DISEASE; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MORTALITY; PREVALENCE; TREATMENT OUTCOME;

EID: 33644941723     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13084869     Document Type: Article

References (30)

1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-55.
2. CIBIS-II Investigators and Committees. The cardiac Insufficiency Bisoprolol Study II (CIBIS-II). Lancet. 1999;353:9-12.
3. The MERIT-HF investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
4. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A bayesian metaanalisis. Ann Intern Med. 2001;134:50-60.
5. Sin DD, McAlister FA. The effects of betablockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med. 2002;113:650-6.
6. Mahmoudi M, MacDonagh S, Poole-Wilson PA, Dubrey SW. Obstacles to the initiation of betablockers for heart failure in a specialised clinic within a district general hospital. Heart. 2003;89:442-4.
7. Chaterjee K. The fear of beta-blocker therapy in heart failure. JAMA. 2004;164:1370-1.
8. Anguita Sánchez M y los investigadores del registro BADAPIC. Características clínicas, tratamiento y morbimortalidad a corto plazo de pacientes con insuficiencia cardíaca controlados en consultas específicas de insuficiencia cardíaca. Resultados del registro BADAPIC. Rev Esp Cardiol. 2004;57:1159-69.
9. The Study Group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology, Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe Part 2: treatment. Eur Heart J. 2003;24;464-74.
10. Witham MD, Gillespie ND, Struthers AD. Age is not a significant risk factor for failed trial of betablocker therapy in older patients with chronic heart failure. Age and Ageing. 2004;33:467-72.
11. ACC/AHA TTGuidelinesTT for the Evaluation and Management of Chronic TTHeart TTTTFailureTT in the Adult [consultado 14/03/2005). Disponible en: www.acc.org/clinical/guidelines/failure/pdfs/hf_fulltext.pdf
12. Remme WJ, Swedberg K, for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-60.
13. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol. 1993;22:6A-13.
14. Rodríguez Artalejo F, Banegas Banegas JR, Guallar-Castillón P. Epidemiología de la insuficiencia cardíaca. Rev Esp Cardiol. 2004;57:163-70.
15. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194-9.
16. Flatcher MD, Shibata MC, Cotas AJS, Van Veldhuisen JV, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nevibolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-22.
17. Smith NL, Chan JD, Rea TD, Wiggins KL, Gottdiener JS, Lumley T, et al. Time trends in the use of beta-blockers and others pharmacotherapies in older adults with congestive heart failure. Am Heart J. 2004;148:710-7.
18. Cleland JGF, Cohen Solal A, Cosin Aguilar JM, Dietz R, Eastaugh J, Follath F, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet. 2002;360:1631-9.
19. Salvador MJ, Sebaoun A, Sonntag F, Blanch P, Silber S, Aznar J, et al. Estudío europeo del tratamiento ambulatorio de la insuficiencia cardíaca realizado por cardiólogos. Rev Esp Cardiol. 2004;57:1170-8.
20. Román-Sánchez P, Conthe P, García-Alegría J, Forteza-Rey J, Montero M, Montoto C, for the Herat Failure Working Group of the Spanish Society of Internal Medicine. Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey. Q J Med. 2005;98:127-38.
21. Urrutia A, Lupón J, González B, Parajón T, Altimir S, Coll R, et al. Prevalencia de anemia y su correlación con parámetros clínicos en pacientes atendidos en una Unidad Interdisciplinar de Insuficiencia Cardiaca. Med Clin (Barc). 2004;122:121-5.
22. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137:715-25.
23. Au DH, Bryson CL, Fan VS, Udris EM, Curtis JR, McDonell MS, et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med. 2004;117:925-31.
24. Tandon P, McAlister FA, Tsuyuki RT, Hervas-Malo M, Dupuit R, Ezekowitz J, et al The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. Arch Intern Med. 2004;164:769-74.
25. Deedwania P, Gottlieb S, Ghali J, Waagstein F, Wikstrand J, for the MERIT-HF Study Group. Efficacy, safety and tolerability of β-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J. 2004;25:1300-9.
26. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.
27. Simon T, Mary-Krause M, Funck-Brentano C, Lechat Ph, Jaillon P, on behalf of CIBIS II investigators. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS-II). Eur Heart J 2003;24:552-9.
28. Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, et al. Adverse effects of betablocker therapy for patients with heart failure. A quantitative overview of randomised trials. Arch Intern Med. 2004;164:1389-94.
29. Dulin BR, Haas SJ, Abraham WT, Krum H. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of > 12,000 patients in large-scale clinical trials. Am J Cardiol. 2005;95:896-8.
30. Urrutia A, Lupón Rosés J, Herreros J, González B, Parajón T, Coll R, et al. Parameters associated with 1 year mortality and related hospital admission rate in an outpatient population assisted in a heart failure unit. Rev Clin Esp. 2004;204 Supl 1:206.